Aurinia receives notice of allowance from the US Patent and Trademark Office for claims directed to its novel voclosporin dosing protocol for lupus nephritis
Monday, February 25, 2019 | Sentiment: Positive | DrugName : voclosporin Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company
Read More